Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
- Trial name
- ADOREXT (NCT05866926)
- Testing
- FAB122
- Where
- Spain
- Volunteers
- 201 people
- Sponsor
- Ferrer Internacional S.A.
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases
- Trial name
- CENTAUR (NCT03127514)
- Testing
- AMX0035
- Where
- 25 sites in United States
- Volunteers
- 137 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation.
- Trial name
- VALOR (Part C) (NCT02623699)
- Testing
- Tofersen
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Therapy in Amyotrophic Lateral Sclerosis (TAME)
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their…
- Trial name
- TAME (NCT02118727)
- Testing
- Memantine
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Kansas Medical Center
Amyotrophic Lateral Sclerosis
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01709149
- Testing
- CK-2017357, Riluzole
- Where
- 75 sites in United States, Canada and 6 more
- Volunteers
- 711 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis (ALS)
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores…
- Trial name
- NCT01492686
- Testing
- MCI-186, MCI-186 in open label phase
- Where
- Japan
- Volunteers
- 137 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis, Parkinson Disease
Physiological Flow of Liquids Used in Dysphagia Management (Neuro)
For individuals with neurodegenerative conditions, such as Amyotrophic Lateral Sclerosis and Parkinson disease, swallowing impairment (i.e., dysphagia) is a common and serious symptom.
- Conditions
- Amyotrophic Lateral Sclerosis, Parkinson Disease, Dysphagia
- Trial name
- NCT03192358
- Testing
- Videofluoroscopic Swallowing Examination, Tongue Strength Measurement
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Spinal Muscular Atrophy
Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
The purpose of this study is to assess whether 4-AP (Dalfampridine-ER, Ampyra) improves walking ability and endurance in adult patients with Spinal muscular atrophy (SMA) Type 3 compared to placebo and whether the duration of…
- Trial name
- NCT01645787
- Testing
- 4-aminopyridine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Spinal Muscular Atrophy 1
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
The purpose of this trial is to evaluate safety and efficacy of intravenous delivery of AVXS-101 as a treatment of spinal muscular atrophy Type 1 (SMN1).
- Trial name
- NCT02122952
- Testing
- AVXS-101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Novartis Gene Therapies
Spinal Muscular Atrophy Type I
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I
The purpose of this study is to identify the maximum tolerated dosage of sodium phenylbutyrate in children with spinal muscular atrophy type I; and to determine if the drug has an effect on SMN mRNA and protein levels.
- Trial name
- NPTUNE 02 (NCT00439218)
- Testing
- sodium phenylbutyrate
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Westat
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.
Spinal Muscular Atrophy
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA)…
- Trial name
- Jewelfish (NCT03032172)
- Testing
- Risdiplam
- Where
- 24 sites in United States, Belgium and 7 more
- Volunteers
- 174 people
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
ALS and Airway Clearance (ALSAC) Therapy
Patients will receive one of three respiratory therapy interventions for airway clearance assistance: 1) High frequency chest wall oscillation (HFCWO) and mechanical insufflation/exsufflation (MIE), 2) HFCWO or 3) MIE.
- Trial name
- ALSAC (NCT04947436)
- Testing
- High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Amyotrophic Lateral Sclerosis
Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials
Trials evaluating new therapies for stopping or slowing the progression of ALS depend critically upon the use of outcome measures to assess whether a potential treatment is effective.
- Trial name
- NCT00620698
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Beth Israel Deaconess Medical Center
Amyotrophic Lateral Sclerosis
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
This is a multi-center, 20-week study of inosine treatment. Study Objectives and Endpoints The primary objective of the study is to determine the safety and tolerability of oral administration of inosine (administered daily)…
- Trial name
- SURE-ALS2 (NCT03168711)
- Testing
- Inosine
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Primary Lateral Sclerosis
Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis
The goal of this clinical trial is to determine if non-invasive electrical stimulation, using an electric stimulator placed on the skin of the patients back and abdomen for 30 minutes can reduce muscle spasms (spasticity) and…
- Trial name
- NCT06012110
- Testing
- Transcutaneous electrical stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nova Southeastern University
ALS (Amyotrophic Lateral Sclerosis)
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
- Trial name
- NCT03241784
- Testing
- Autologous T-regulatory lymphocytes, Interleukin-2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Methodist Hospital Research Institute
Spinal Muscular Atrophy
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in…
- Trial name
- SHINE (NCT02594124)
- Testing
- nusinersen
- Where
- 47 sites in United States, Australia and 12 more
- Volunteers
- 292 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
The purpose of this study was to evaluate the safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis as compared to Placebo.
- Trial name
- REViVALS-1A (NCT04632225)
- Testing
- Engensis
- Where
- 5 sites in United States, South Korea
- Volunteers
- 18 people
- Sponsor
- Helixmith Co., Ltd.
Spinal and Bulbar Muscular Atrophy
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
- Trial name
- NCT02024932
- Testing
- BVS857
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals